Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Peritoneal Carcinoma: early-phase trial registry
6 of 21 indexed Primary Peritoneal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 6 currently recruiting · #797 of 28,707 conditions by registered trial count
Primary Peritoneal Carcinoma: 21 US clinical trials tracked, 6 recruiting.
Primary Peritoneal Carcinoma is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Gynecologic Oncology Group, running 2 of these trials.
Enrollment posture brief
Registry condition primary-peritoneal-carcinoma
OPEN 6 | RECR 29% | LATE 1 | EARLY 15 | RANK #797 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)
Primary Peritoneal Carcinoma lists 6 open slots (29% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Peritoneal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Peritoneal Carcinoma is recruiting below its size-band peers.
6 of 21 indexed trials (28.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Primary Peritoneal Carcinoma trials is spread across many organizations.
Gynecologic Oncology Group accounts for 2 of 21 trials (9.5%). 19 distinct sponsors appear on at least one study for this condition label.
-
Typical Primary Peritoneal Carcinoma enrolment sits around 70 participants.
Median target enrolment is 70 among the 21 trials that report a genuine target (sentinel values excluded). 12 of those (57.1%) plan for fewer than 100 participants.
-
Primary Peritoneal Carcinoma research is mostly interventional.
17 interventional and 4 observational studies make up this index (81% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
M.D. Anderson Cancer Center
NCT00488878
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT05579366
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT06915025
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
NCT03604315
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
NCT06469281
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
NCT06492070
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT05527184
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe
NCT05199272
A Study of Sovilnesib in Subjects With Ovarian Cancer
Volastra Therapeutics
NCT06084416
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
NCT06483997
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT02345265
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
OncoC4
NCT05446298
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Brown University
NCT03355976
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Mercy Medical Center
NCT02124421
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT04204811
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
Gynecologic Oncology Group
NCT01139957
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Accelerated Community Oncology Research Network
NCT00407563
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Gynecologic Oncology Group
NCT00939809
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Washington University School of Medicine
NCT01308944
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Tracon Pharmaceuticals
NCT01381861
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center
NCT03604653
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Peritoneal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Peritoneal Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Peritoneal Carcinoma page
21 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Primary Peritoneal Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Gynecologic Oncology Group sponsors the most Primary Peritoneal Carcinoma trials on record, review their full trial history before evaluating a specific study. See Gynecologic Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Peritoneal Carcinoma condition card totals 21 registered trials; most-linked intervention Carboplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.